CONTACT
ABOUT ABBOTT
cardiovascular
MY ACCOUNT

Xience™ Family of Drug Eluting Stents

THE WORLD'S LEADING DRUG-ELUTING STENTS (DES), WITH UNPARALLELED CLINICAL OUTCOMES1

Xience™ drug-eluting stents
Xience™ drug-eluting stents
Xience™ drug-eluting stents

     

            XIENCE™ SIERRA

48-mm for Long Lesions

Clinical Evidence in Long Lesions with 48 mm XIENCE™ Stent

The XIENCE Skypoint™ 48 mm Stent is designed so that interventional cardiologists (ICs) can use only one stent in long coronary lesions. Diffuse coronary disease—with long lesions—can otherwise be challenging when employing multiple stents.2

XIENCE Skypoint 48-mm Stent for long lesions can preclude the need for multiple overlapping stents.

Advantages in Using a Single Long Stent2

There are several advantages in using a single long stent vs several shorter stents in percutaneous coronary intervention (PCI):

  • Reduces procedure time, making PCIs faster and more efficient
  • Reduces radiation and fluoroscopy time
  • Reduces use of contrast

Use of a single longer stent, vs 2 shorter stents, also reduces overlap. In fact, stent overlap has been reported in as many as 30% of patients undergoing PCI. Overlapping stents may also result in:

  • Increased risk of stent fracture3
  • Higher rates of target lesion revascularization (TLR)2

XIENCE Skypoint™ Stent also offers a 4.0 x 48mm stent size to help treat larger vessels where there may be diffuse disease.

   

XIENCE™ 48 mm Stent Safety Outcomes†

Long XIENCE™ Stents continue the tradition of excellent XIENCE™ safety outcomes. XIENCE™ 48 mm Stents demonstrate impressive outcomes in long lesions:

  • 100% device success (mean stented length 58 mm)4
  • 0.1% definite/probable stent thrombosis (ST) 24 hours post-procedure (mean stented length 39.3 mm)5

Data from XIENCE Prime™ Stent & XIENCE Xpedition™ Stent
 

In long lesions, XIENCE 48-mm stents achieved 100% device success.
In long lesions, 48-mm stents achieved 0.1% acute definite or probable stent thrombosis.

Long-Term Outcomes in Long, Complex Lesions4

When using XIENCE™ 48 mm Stents in long, complex lesions, there were low rates of myocardial infarction (MI), TLR, and major adverse cardiac events (MACE) 1 year after the index procedure. In this analysis the mean stented length was 58 mm.

When treating long, complex lesions, XIENCE Stent 1-year data showed 0.8% MI, 0.8% TLR, and 3.3% MACE rates.

Consistent Outcomes with Moderate / Long Length Stents6

Additional data supported the safety of XIENCE™ Stent in long lesions, with findings displaying consistent performance between moderate length lesions and long lesions.

 Moderate Length Lesions
(> 24 mm to < 35 mm)
482 patients		Long Length Lesions
(> 35 mm)
323 patients		p value
TLF at 1 Year10%8.9%p = 0.63
Mean Lesion Length28.1 mm47.1 mmp < 0.0001

Lower Revascularization in Chronic Total Occlusions (CTO)7

Among the 3-year outcomes of the PRISON-IV trial, the XIENCE™ Stent resulted in significantly lower TLR rates of 4.2% compared to 11.5% with biodegradable polymer sirolimus-eluting stents (BP-SES). The population encompassed patients with complex CTOs.

  • Total stented length with XIENCE™ Stent: 52.3 mm
  • Total stented length with BP-SES: 52.4 mm
When treating CTOs in long lesions, XIENCE Stent has significantly lower target lesion revascularization rate of 4.2% vs 11.5% with BP-SES.

Excellent Long-Term Outcomes at 5 Years8

The 5-year data from the IVUS-XPL study reveal excellent XIENCE™ Stent outcomes in long lesion treatment guided by intravascular ultrasound (IVUS). Study results show low event rates with long lesions treated with long stents.

  • Mean lesion length: 35.1 mm
  • Total stented length: 39.4 mm

Note the low rates of both definite or probable ST (0.3%) and MACE (5.6%).

XIENCE Stent has much lower platelet adhesion compared to Synergy, Orsiro, Ultimaster, Onyx, and BioFreedom drug-eluting stents

Abbott’s Coronary Intervention Portfolio

† XIENCE™ Stent safety outcomes include data on XIENCE Prime™ Stent & XIENCE Xpedition™ Stent.
 

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Jurado-Román A, et al. Cardiovasc Revasc Med. 2019;20(8):681-686.
  3. Chinikar M, et al. Current Cardiol Rev. 2014;10:349-354.
  4. Tan CK, et al. Herz. 2019;44:419-424
  5. Hong SFJ, et al. J Am Coll Cardiol Intv. 2016;9:1438-1446.
  6. Bouras G, et al. Catheter Cardiovasc Interv. 2017;89(6):984-991.
  7. Zivelonghi C, et al. JACC Cardiovasc Interv. 2019;12(17):1747-1749. Teeuwen K, et al. JACC Cardiovasc Interv. 2017;10(2):133-143.
  8. Hong SJ, et al. JACC Cardiovasc Interv. 2020;13(1):62-71.

MAT-2305699 V1.0

 

Abbott Logo

Information contained herein for distribution in Australia and New Zealand only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

Abbott Vascular division of Abbott Medical New Zealand Ltd, Grd Flr, Bldg. D, 4 Pacific Rise Mt Wellington, Auckland 1060 Tel: 0800 827 285

Abbott Vascular division of Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park NSW 2113, Tel: 1800 550 939

© 2024 Abbott. All Rights Reserved.

MAT-2105201 v6.0

Disclaimer

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

 

Do you wish to continue and enter this website?

 MAT-2408064 V1.0